ECSP11011167A - Síntesis y formas de sales novedosas de (r) -5- ( (e) -2- (pirrolidin-3-ilvinil) pirimidina - Google Patents

Síntesis y formas de sales novedosas de (r) -5- ( (e) -2- (pirrolidin-3-ilvinil) pirimidina

Info

Publication number
ECSP11011167A
ECSP11011167A EC2011011167A ECSP11011167A ECSP11011167A EC SP11011167 A ECSP11011167 A EC SP11011167A EC 2011011167 A EC2011011167 A EC 2011011167A EC SP11011167 A ECSP11011167 A EC SP11011167A EC SP11011167 A ECSP11011167 A EC SP11011167A
Authority
EC
Ecuador
Prior art keywords
pyrimidine
forms
synthesis
ilvinil
pirrolidin
Prior art date
Application number
EC2011011167A
Other languages
English (en)
Inventor
Gary Maurice Dull
Craig H Miller
Srinivisa Rao Akireddy
Julio A Munoz
Timothy J Cuthbertson
Joseph Pike Mitchener
Pieter Albert Otten
Balwinder Singh Bhatti
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41650077&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011167(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of ECSP11011167A publication Critical patent/ECSP11011167A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se relaciona con la síntesis estereoespecífica de R)-5-((E)-2-pirrolidin-3-ilvinil) pirimidina, sus formas de sales y formas polimórficas novedosas de estas sales.
EC2011011167A 2008-12-01 2011-06-29 Síntesis y formas de sales novedosas de (r) -5- ( (e) -2- (pirrolidin-3-ilvinil) pirimidina ECSP11011167A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11879608P 2008-12-01 2008-12-01
PCT/US2009/066078 WO2010065443A1 (en) 2008-12-01 2009-11-30 Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine

Publications (1)

Publication Number Publication Date
ECSP11011167A true ECSP11011167A (es) 2011-10-31

Family

ID=41650077

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011167A ECSP11011167A (es) 2008-12-01 2011-06-29 Síntesis y formas de sales novedosas de (r) -5- ( (e) -2- (pirrolidin-3-ilvinil) pirimidina

Country Status (25)

Country Link
US (1) US8604191B2 (es)
EP (2) EP2364307B1 (es)
JP (1) JP5710490B2 (es)
KR (1) KR20110098763A (es)
CN (1) CN102232070A (es)
AU (1) AU2009322624B2 (es)
BR (1) BRPI0922759A2 (es)
CA (2) CA3090738C (es)
CL (1) CL2011001258A1 (es)
CO (1) CO6390106A2 (es)
DK (1) DK3279195T3 (es)
EC (1) ECSP11011167A (es)
ES (2) ES2641762T3 (es)
HU (1) HUE050540T2 (es)
IL (2) IL266097B (es)
MX (1) MX2011005611A (es)
NZ (3) NZ703381A (es)
PE (1) PE20110589A1 (es)
PL (1) PL3279195T3 (es)
PT (1) PT3279195T (es)
RU (2) RU2533819C2 (es)
SG (2) SG10201902903RA (es)
UA (1) UA107336C2 (es)
WO (1) WO2010065443A1 (es)
ZA (1) ZA201103737B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145396B2 (en) * 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
US20130237550A1 (en) * 2010-03-11 2013-09-12 Targacept, Inc. Arylvinylazacycloalkane compounds for constipation
CN107106542B (zh) 2014-10-20 2020-05-08 奥伊斯特普安生物制药公司 治疗眼部病状的方法
NZ746468A (en) 2016-04-07 2023-06-30 Oyster Point Pharma Inc Methods of treating ocular conditions
WO2020014217A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
EP3820443A1 (en) 2018-07-10 2021-05-19 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
EP4142734B1 (en) 2020-04-28 2025-08-20 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649041A (en) * 1983-07-20 1987-03-10 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of antinauseants
SU1605922A3 (ru) * 1987-05-01 1990-11-07 Фудзисава Фармасьютикал Ко., Лтд (Фирма) Способ получени производных пирролидина или их солей
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
ES2097703B1 (es) * 1995-04-12 1997-12-01 Decox S L Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion.
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
US6310043B1 (en) 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
JP2003513054A (ja) * 1999-11-01 2003-04-08 ターガセプト，インコーポレイテッド アリールオレフィンアザ環式化合物及びアリールアセチレンアザ環式化合物、それらを含有する薬剤組成物、及び、ニコチンコリン作動性受容体の阻害薬としてのそれらの使用
EP1302458A4 (en) * 2000-07-11 2005-10-19 Banyu Pharma Co Ltd ESTERDERIVATE
WO2003013526A1 (en) * 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
US6872827B2 (en) * 2002-04-26 2005-03-29 Chembridge Research Laboratories, Inc. Somatostatin analogue compounds
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
JP5162236B2 (ja) * 2004-03-25 2013-03-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ イミダゾール化合物
AR053364A1 (es) * 2005-04-20 2007-05-02 Smithkline Beecham Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
TW201024283A (en) * 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine

Also Published As

Publication number Publication date
ZA201103737B (en) 2012-01-25
PL3279195T3 (pl) 2020-12-14
IL212798B (en) 2019-05-30
RU2014136983A (ru) 2016-04-10
UA107336C2 (ru) 2014-12-25
RU2700796C2 (ru) 2019-09-23
CN102232070A (zh) 2011-11-02
SG10201902903RA (en) 2019-05-30
HUE050540T2 (hu) 2020-12-28
EP3279195A1 (en) 2018-02-07
ES2641762T3 (es) 2017-11-13
ES2820857T3 (es) 2021-04-22
EP2364307A1 (en) 2011-09-14
CA3090738C (en) 2023-06-13
IL266097B (en) 2022-07-01
AU2009322624A1 (en) 2010-06-10
AU2009322624B2 (en) 2015-06-11
WO2010065443A1 (en) 2010-06-10
MX2011005611A (es) 2011-09-15
CA2742366C (en) 2020-09-22
IL212798A0 (en) 2011-07-31
SG10201406410UA (en) 2014-11-27
NZ592554A (en) 2013-08-30
PE20110589A1 (es) 2011-09-07
CO6390106A2 (es) 2012-02-29
JP2012510471A (ja) 2012-05-10
BRPI0922759A2 (pt) 2016-01-05
CL2011001258A1 (es) 2011-09-02
CA3090738A1 (en) 2010-06-10
NZ703381A (en) 2016-03-31
RU2533819C2 (ru) 2014-11-20
EP3279195B1 (en) 2020-07-01
DK3279195T3 (en) 2020-08-17
KR20110098763A (ko) 2011-09-01
US8604191B2 (en) 2013-12-10
NZ611965A (en) 2015-01-30
RU2011127010A (ru) 2013-01-10
IL266097A (en) 2019-06-30
PT3279195T (pt) 2020-09-29
EP2364307B1 (en) 2017-07-05
US20110281895A1 (en) 2011-11-17
CA2742366A1 (en) 2010-06-10
HK1250572A1 (en) 2018-12-28
JP5710490B2 (ja) 2015-04-30

Similar Documents

Publication Publication Date Title
CY1125421T1 (el) Ριβονουκλεϊκα οξεα που περιεχουν ν1-μεθυλο- ψευδοουρακιλες και χρησεις αυτων
ECSP10010366A (es) Derivados de pirimidina 5-fluoro como fungicidas
MX373860B (es) Pirimidinas modificadas en la posición 5 y su uso.
UY34219A (es) Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
ECSP14013251A (es) Derivados de 5-flúor-4-imino-3-(sustituido)-3,4-dihidropirimidin-2(1h)ona
UA116920C2 (uk) Інгібітори fgfr4
TN2015000521A1 (en) Processes of making and crystalline forms of a mdm2 inhibitor
GT200600315A (es) Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
SMT201600267B (it) Inibitori di syk imidazopirazinici
NI201200023A (es) Derivados de 5-fluoropirimidinona
EP2443123A4 (en) SPLEEN TYROSIN KINASE SMALL MOLECULE HEMMER
MX2009005829A (es) Polialquileniminas hidrofobicamente modificadas para usarse como inhibidores de transferencia de colorante.
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
UY34380A (es) ?determinación de polimorfismos de nucleótido simple útiles para predecir la respuesta clínica al acetato de glatirámero?.
CO6491115A2 (es) Derivados de 5-fluoro - 2 oxopirimidona-1 (2h)-carboxamida substituida -n1
CR20120030A (es) Derivados de n1-acil-5-fluoropirimidinona
DK2117564T3 (da) Anvendelse af chitosaner til forøgelse af neglevæksthastigheden
UA107336C2 (ru) Синтез и солевые формы (r)-5-((e)-2-пирролидин-3-илвинил) пиримидина
ECSP13012914A (es) Síntesis de derivados de 2-carboxamida-cicloamino-urea
CR11332A (es) Co-cristales de pirimetanilo y ditianona
HN2011000745A (es) Sales de n-[6-cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4´-(triflouro-metoxi)-[1,1´-bifenil]-3-carboxamida
UY32278A (es) Sintesis y formas de sales novedosas de (r) -3-((e)-2-(pyrolidin-3-il)vinil(-5-(tetrahidropiran-4-iloxi)piridina
PA8796801A1 (es) Sintesis quiral de diazepinoquinolinas
IT1400395B1 (it) Processo one-pot per la sintesi di dalfampridine.
UY32042A (es) Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90